Personalized interferon therapy aims to tame kidney disease without weakening defenses
NCT ID NCT05941845
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injections based on their immune profile, with the goal of reducing harmful antibodies and protein leakage without increasing infection risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Peginterferon alfa-2a (Pegasys)
What this could lead to
If successful, this approach could offer a targeted, infection-sparing alternative to standard immunosuppressive treatments for membranous nephropathy.
What could go wrong
This is a very small early-phase trial with only 4 participants, so results may not generalize. Interferon therapy can cause flu-like symptoms and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de NICE
Nice, France